MétaCan
Menu
Back to cohort

Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial

2025· article· en· W4413292306 on OpenAlexafffund
David D. Berg, Kieran F. Docherty, Atefeh Talebi, Naveed Sattar, Petr Jarolı́m, Paul Welsh, Pardeep S. Jhund, Inder S. Anand, Rudolf A. de Boer, Eri Kato, Lars Køber, Felipe A Martinez, Eileen O’Meara, Piotr Ponikowski, Morten Schou, Scott Solomon, Ann Hammarstedt, John J.V. McMurray, Marc S. Sabatine, David A. Morrow

Bibliographic record

VenueJournal of Cardiac Failure · 2025
Typearticle
Languageen
FieldMedicine
TopicGDF15 and Related Biomarkers
Canadian institutionsUniversité de MontréalMontreal Heart Institute
FundersCanadian Institutes of Health ResearchAmerican RegentInstitut de Cardiologie de MontréalVifor PharmaAstellas PharmaEisaiAlexion PharmaceuticalsUniversity of GlasgowARCA BiopharmaSanofiAbiomedImpulse DynamicsNovo NordiskDaiichi-SankyoIntarcia TherapeuticsDefense Acquisition Program AdministrationBoston Scientific CorporationAlnylam PharmaceuticalsAbbott VascularBrigham and Women's HospitalServierBayerBristol-Myers SquibbOno PharmaceuticalEli Lilly and CompanyAstraZenecaSiemens HealthineersAmgenLivaNovaPfizerKowa CompanyAbbott Laboratories
KeywordsMedicineDapagliflozinHeart failureInternal medicinePharmacologyEndocrinology

Abstract

fetched live from OpenAlex

BACKGROUND: Growth differentiation factor (GDF)-15, a stress-induced cytokine implicated in systemic energy homeostasis, is associated with adverse outcomes in heart failure (HF). This study evaluated the associations between baseline GDF-15 and the clinical characteristics and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial. The effect of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on circulating GDF-15 levels and the effect of dapagliflozin on clinical outcomes in relation to baseline GDF-15 concentrations were also examined. METHODS AND RESULTS: DAPA-HF was a randomized trial of dapagliflozin in patients with HF and LVEF ≤ 40%. GDF-15 was measured at baseline and 12 months. The primary outcome was the composite of worsening HF or cardiovascular death. The median baseline GDF-15 level was 1888 (IQR: 1323-2755) pg/mL. Higher GDF-15 levels were associated with older age, lower body mass index, and greater HF symptom burden. There was a stepwise increase in adjusted risk for the primary outcome across quartiles of baseline GDF-15 (adjusted hazard ratio [Q4 vs Q1] 2.30, 95% CI 1.66-18; P trend < 0.001). Dapagliflozin did not significantly change GDF-15 concentrations over 12 months, compared to placebo (placebo-corrected relative change +4%; 95% CI, -2% to +10%). The relative effect of dapagliflozin on the primary outcome was consistent across GDF-15 quartiles (P interaction = 0.96), with a greater absolute benefit in those with higher GDF-15 (P trend < 0.01). CONCLUSIONS: In DAPA-HF, GDF-15 was independently prognostic of worsening HF or cardiovascular death. Absolute risk reduction with dapagliflozin was greater in patients with higher baseline GDF-15, but the benefit was not associated with an effect on GDF-15 itself.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.226
Teacher spread0.222 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractno

Explore more

Same venueJournal of Cardiac FailureSame topicGDF15 and Related BiomarkersFrench-language works237,207